Paid Clinical Trials in Hackensack, NJ

As of June 2026, 332 paid clinical trials are recruiting in Hackensack, New Jersey. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.

Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

332 clinical trials

↓ Download CSV

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

for Multiple Sclerosis

17 locations incl. Birmingham

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18 - 60

Code: NCT06220201·Phase 1·Recruiting

Apply to this trial

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

for Focal Epilepsy

61 locations incl. Phoenix

Sponsor: Biohaven Therapeutics Ltd.

Sex: All·Age: 18 - 75

Code: NCT06132893·Phase 2, Phase 3·Recruiting

Apply to this trial

Study of AZD0754 in Participants With Metastatic Prostate Cancer

for Metastatic Prostate Cancer

13 locations incl. Duarte

Sponsor: AstraZeneca

Sex: Male·Age: 18 - 130

Code: NCT06267729·Phase 1, Phase 2·Recruiting

Apply to this trial

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

for AML

38 locations incl. Gilbert

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT06001788·Phase 1·Recruiting

Apply to this trial

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

for Multiple Myeloma

17 locations incl. Birmingham

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06121843·Phase 1·Recruiting

Apply to this trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for Muscle Invasive Bladder Urothelial Carcinoma

490 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05987241·Phase 2, Phase 3·Recruiting

Apply to this trial

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

for Pancreatic Ductal Adenocarcinoma

2 locations incl. Washington D.C.

Sponsor: Georgetown University

Sex: All·Age: 18+

Code: NCT06015724·Phase 2·Recruiting

Apply to this trial

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

for Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Drug: Epcoritamab

6 locations incl. Rochester

Sponsor: Academic and Community Cancer Research United

Sex: All·Age: 18+

Code: NCT06238648·Phase 2·Recruiting

Apply to this trial

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

for SCLC

11 locations incl. Duarte

Sponsor: Zai Lab (Shanghai) Co., Ltd.

Sex: All·Age: 18+

Code: NCT06179069·Phase 1·Recruiting

Apply to this trial

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

for Multiple Myeloma

Drug: Talquetamab

49 locations incl. Clovis

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06208150·Phase 3·Recruiting

Apply to this trial

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

for Refractory Non-Hodgkin Lymphoma

3 locations incl. Duarte

Sponsor: SIRPant Immunotherapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05967416·Phase 1·Recruiting

Apply to this trial

A Global Study of the PETAL Consortium

for T-Cell and NK-Cell Neoplasm

10 locations incl. Duarte

Sponsor: Massachusetts General Hospital

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT06067347·Recruiting

Apply to this trial

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

for Recurrent Glioma

27 locations incl. Aurora

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05859334·Phase 2·Recruiting

Apply to this trial

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

for Solid Tumors

Drug: INCB161734

16 locations incl. Phoenix

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT06179160·Phase 1·Recruiting

Apply to this trial

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

for Hypertension

70 locations incl. Scottsdale

Sponsor: Orchestra BioMed, Inc

Sex: All·Age: 18+

Code: NCT06059638·Recruiting

Apply to this trial

Evaluation of the Effects of Ketorolac Dose on Duration of Analgesia in Emergency Department (ED) Renal Colic Patients

for Renal Colic

1 location in Hackensack

Sponsor: Hackensack Meridian Health

Sex: All·Age: 18 - 65

Code: NCT05776953·Phase 4·Recruiting

Apply to this trial

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

for Locally Advanced Head and Neck Squamous Cell Carcinoma

70 locations incl. Birmingham

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT06129864·Phase 3·Recruiting

Apply to this trial

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

for Chronic Lymphocytic Leukemia

Drug: Nemtabrutinib

43 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136559·Phase 3·Recruiting

Apply to this trial

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

for Advanced Solid Tumor

23 locations incl. Tucson

Sponsor: Eikon Therapeutics

Sex: All·Age: 18 - 89

Code: NCT06253130·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

for Non-small Cell Lung Cancer

Drug: Intismeran autogene

68 locations incl. Anchorage

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06077760·Phase 3·Recruiting

Apply to this trial

A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia

for B Acute Lymphoblastic Leukemia Associated With Down Syndrome

69 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 6 - 39

Code: NCT05702645·Recruiting

Apply to this trial

The Fourth Left Atrial Appendage Occlusion Study

for Atrial Fibrillation

51 locations incl. Birmingham

Sponsor: Hamilton Health Sciences Corporation

Sex: All·Age: 18+

Code: NCT05963698·Recruiting

Apply to this trial

Evaluation of the GORE® Ascending Stent Graft

for Aortic Aneurysm, Thoracic

41 locations incl. Birmingham

Sponsor: W.L.Gore & Associates

Sex: All·Age: 18+

Code: NCT05800743·Enrolling By Invitation

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

for Carcinoma, Non-small-Cell Lung

7 locations incl. Newnan

Sponsor: Johnson & Johnson Enterprise Innovation Inc.

Sex: All·Age: 18+

Code: NCT06116786·Phase 1·Recruiting

Apply to this trial

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

for Heart Failure

31 locations incl. Birmingham

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 40 - 85

Code: NCT06122779·Phase 2·Recruiting

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1208 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting

Apply to this trial

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

for Acute Coronary Syndrome

178 locations incl. Alexander City

Sponsor: DalCor Pharmaceuticals

Sex: All·Age: 45+

Code: NCT05918861·Phase 3·Recruiting

Apply to this trial

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

for Carcinoma, Non-Small-Cell Lung

3 locations incl. Washington D.C.

Sponsor: Hackensack Meridian Health

Sex: All·Age: 18+

Code: NCT05715229·Phase 2·Recruiting

Apply to this trial

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

for Advanced Solid Tumor

9 locations incl. Duarte

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT05981703·Phase 1·Recruiting

Apply to this trial

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

for Mucopolysaccharidosis II

8 locations incl. Oakland

Sponsor: Denali Therapeutics Inc.

Sex: All·Age: Up to 18

Code: NCT06075537·Phase 2, Phase 3·Enrolling By Invitation

Left vs Left Randomized Clinical Trial

for Heart Failure

57 locations incl. Gilbert

Sponsor: Baylor College of Medicine

Sex: All·Age: 18+

Code: NCT05650658·Recruiting

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

for Metastatic Breast Cancer

20 locations incl. Gilbert

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT05894239·Phase 3·Recruiting

Apply to this trial

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

for Ph+ ALL

16 locations incl. Birmingham

Sponsor: Ascentage Pharma Group Inc.

Sex: All·Age: 18+

Code: NCT06051409·Phase 3·Recruiting

Apply to this trial

Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

for Heart Failure

47 locations incl. Phoenix

Sponsor: Procyrion

Sex: All·Age: 21+

Code: NCT05677100·Recruiting

Apply to this trial

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

for Cardiovascular Disorder

31 locations incl. Mobile

Sponsor: Children's Oncology Group

Sex: All·Age: 7+

Code: NCT05705531·Recruiting

Apply to this trial

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

for Solid Tumors

11 locations incl. Los Angeles

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT05836324·Phase 1·Recruiting

Apply to this trial

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

for Relapsed/Refractory Multiple Myeloma

36 locations incl. Birmingham

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT05850234·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

for Acute Myeloid Leukemia

Drug: Venetoclax

44 locations incl. Phoenix

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT05735184·Phase 1·Recruiting

Apply to this trial

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

for Atrial Fibrillation

93 locations incl. Phoenix

Sponsor: Johns Hopkins University

Sex: All·Age: 22 - 85

Code: NCT05836987·Phase 3·Recruiting

Apply to this trial

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

for Metastatic Solid Tumors

4 locations incl. Chicago

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT05853367·Phase 1·Recruiting

Apply to this trial